Pharmacological and clinical aspects of fluvoxamine (Depromel®), the first selective serotonin reuptake inhibitor approved for clinical use employed in Japan

Folia Pharmacologica Japonica

Volumn 115, Issue 5, 2000, Pages 271-279

  Hachisu, Mitsugu ^a   Ichimaru, Yasuyuki ^a  

^a MEIJI SEIKA KAISHA LTD   (Japan)

Author keywords

Depression; Depromel ; Fluvoxamine; Obsessive compulsive disorder (OCD); Selective serotonin reuptake inhibitor (SSRI)

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; FLUVOXAMINE; FLUVOXAMINE MALEATE; HISTAMINE H1 RECEPTOR; MUSCARINIC RECEPTOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

AGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG APPROVAL; DRUG MARKETING; DRUG MECHANISM; DYSURIA; HUMAN; JAPAN; LONG TERM CARE; MAJOR CLINICAL STUDY; OBSESSION; ORTHOSTATIC HYPOTENSION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; REVIEW; SEROTONINERGIC NERVE CELL; TREATMENT INDICATION; VERTIGO; XEROSTOMIA;

EID: 0034028180     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.115.271     Document Type: Review

References (50)

1. Claassen V, Davies JE, Hertting G and Placheta P: Fluvoxamine, a specific 5-hydroxytryptamine uptake inhibitor. Br J Pharmacol 60, 505-516 (1977)
2. th, ed. Edited by Hardman JG and Limbird LE, pp431-459, The McGraw-Hill Co, New York (1996)
3. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H-U and Kendler KS: Lifetime and 12-month prevalence of DSM-III-R Psychiatric disorders in the United States. Arch Gen Psychiatry 51, 8-19 (1994)
4. Krai VA: Masked depression in middle aged men. Can Med Assoc J 79, 1-5 (1958)
5. Schildkraut JJ: The catecholamine hypothesis of affective disorders; a review of supporting evidence. Am J Psychiatry 122, 509-522 (1965)
6. Coppen A: The biochemistry of affective disorders. Br J Psychiatry 113, 1237-1264 (1967)
7. Kuhn R: The treatment of depressive state with G 22355 (imipramine hydrochloride). Am J Psychiatry 115, 459-464 (1958)
8. Korf J and van Prag HM: Endogenous depression with and without disturbances in the 5-hydroxy-tryptamine metabolism. Psychopharmacologia 19, 148-152 (1971)
9. Gibbons RD and Davis JM: Consistent evidence for a biological subtype of depression characterized by low monoamine levels. Acta Psychiatry Scand 74, 8-12 (1986)
10. Drevets WC, Price JL, Simpson JR Jr, Todd RD, Reich T, Vannier M and Raichle ME: Subgenual prefrontal cortex abnormalities in mood disorders. Nature 386, 824-827 (1997)
11. Stahl SM: Chapter 8, Drug treatments for obsessive compulsive disorder, panic disorder and phobic disorder. In Essential Psychopharmacology "Neuroscientific Basis and Practical Applications" pp216-248, Cambridge University Press, Cambridge (1996)
12. Koran LM, McElroy SL, Davidson JR, Rasmussen SA, Hollander E and Jenike MA: Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blined comparison. J Clin Psychopharmacol 16, 121-129 (1996)
13. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC and Murphy DL: Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and health controls. Arch Gen Psychiatry 44, 946-951 (1987)
14. Breiter HC, Rauch L, Kwong KK, Baker JR, Weisskoff RM, Kennedy DN, Kendrick AD, Davis TL, Jiang A, Cohen MS, et al: Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder. Arch Gen Psychiatry 53, 595-606 (1996)
15. Rauch SL, Jenike MA, Alpert NM, Baer L, Breiter HCR, Savage CR and Fischman AJ: Regional cerebral blood flow measured during symptom provocation in obsessive-compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography. Arch Gen Psychiatry 51, 62-70 (1994)
16. Claassen V: Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Br J Clin Pharmacol 15, 349S-355S (1983)
17. Uzunova V, Sheline Y, Davis JM, Rasmussen A, Uzunov DP, Costa E and Guidotti A: Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 95, 3239-3244 (1998)
18. Egawa T, Ichimaru Y, Imanishi T and Sawa A: Neither the 5-HT1A- nor 5-HT2-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on forced-swimming-induced immobility in mice. Jpn J Pharmacol 68, 71-75 (1995)
19. Njung'e K and Handley SL: Evaluation of marbleburying behavior as a model of anxiety. Pharmacol Biochem Behav 38, 63-67 (1991)
20. 1A-receptor subtype mediates the effect of fluvoxamine, a selective serotonin reuptake inhibitor, on marbleburying behavior in mice. Jpn J Pharmacol 68, 65-70 (1995)
21. Tulp M, Mol F, Rademaker B and Schipper J: In vitro pharmacology of fluvoxamine: Inhibition of monoamine uptake, receptor binding profile and functional receptor antagonism. Comparison with tricyclics and mianserin. Depression, Anxiety and Aggression (Medidact), 9-19 (1988)
22. Van Harten J, Van Bemmel P, Dobrinska MR, Ferguson RK and Raghoebar M: Bioavailability of fluvoxamine given with and without food. Biopharm Drug Dispos 12, 571-576 (1991)
23. Carrillo JA, Dahl MI, Svensson JO, Aim C, Rodriguez I and Bertilsson L: Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 60, 183-190 (1996)
24. Ovemars H, Scherpenisse PM and Post LC: Fluvoxamine maleate: metabolism in man. Eur J Drug Metab Pharmacokinet 8, 269-280 (1983)
25. Strauss WL, Layton ME and Dager SR: Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy. Am J Psychiatry 155, 380-384 (1998)
26. Nemeroff CB, DeVane CL and Pollock BG: Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 153, 311-320 (1996)
27. Ketter TA, Flockhart DA, Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS and Callahan AM: The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 15, 387-398 (1995)
28. van Harten J, Holland RL and Wesnes K: Influence of multiple-dose administration of fluvoxamine on the pharmacokinetics of the benzodiazepines bromazepam and lorazepam: a randomised, cross-over study. Eur Neuropsychopharmacol 2, 381 (1992)
29. Heinonen EH and Myllyla V: Safty of selegyline (deprenyl) in the treatment of Parkinson's disease. Drug Saf 19, 11-22, (1998)
30. Graber MA, Hoehns TB and Perry PJ: Sertralinephenelzine drug interaction: a serotonin syndrome reaction. Ann Pharmacother 28, 732-735 (1994)
31. Ohman R and Spigset O: Serotonin syndrome induced fluvoxamine-lithium interaction. Pharmacopsychiatry 26, 263-264 (1993)
32. Terra JL and Montgomery SA: Fluvoxamine prevents recurrence of depression: results of a long-term, double-blind, placebo-controlled study. Int Clin Psychopharmacol 13, 55-62 (1998)
33. Frechilla D, Otano A and Rio JD: Effect of chronic antidepressant treatment on transcription factor binding activity in rat hippocampus and frontal cortex. Prog Neuropsychopharmacol Biol Psychiatry 22, 787-802 (1998)
34. Chaput Y, de Montigny C and Blier P: Effects of a selective 5-HT reuptake blocker, citalopram, on the sensitivity of 5-HT autoreceptors: electrophysiological studies in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 333, 342-348 (1986)
35. O'Connor JJ and Kruk ZL: Effect of 21 days treatment with fluoxetine on stimulated endogenous 5-hydroxytryptamine overflow in the rat dosai raphe and sprachimastic nucleus studied using fast cyclic voltammetry in vitro. Brain Res 640, 328-335 (1994)
36. 1A receptor responsivity in obsessivecompulsive disorder. Psychopharmacology (Berl) 105, 415-420 (1991)
37. Olafsson K, Jorgensen S, Jensen HV, Bile A, Arup P and Andersen J: Fluvoxamine in the treatment of demented elderly patients: a double-blined, placebo-controlled study. Acta Psychiatr Scand 85, 453-456 (1992)
38. Boyer WF and Ewighner JP: Chapter 13 Other uses of the selective serotonin re-uptake inhibitors in psychiatry. In Advances in Basic Research and Clinical Practice, Second Edition, Edited by Feighner JP and Boyer WF, pp267-289, John Wiley & Sons Ltd, New York (1996)